On our screens:Stocks with no debt
The financials
Innoviva, Inc. by the numbers
Innoviva, Inc. (INVA) reported revenue of $98M in Q1 2026 (quarter ended Mar 31, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $187M (190% of revenue). For the full year FY2025, revenue was $411M (+15% year on year) and net income $271M. Its largest product in Jun 2026 was Royalty at $56M, 46% of the disclosed total, well ahead of Xacduro at 18%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $98M | $89M | +11% |
| Gross profit | $76M | $73M | +3.4% |
| Operating income | $38M | $41M | −7.9% |
| Net income | $187M | −$47M | to a profit |
| Diluted EPS | $2.22 | −$0.74 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $56M | 46% |
| Xacduro | $22M | 18% |
| Giapreza | $22M | 18% |
| License And Other | $11M | 9.5% |
| Xerava | $6.7M | 5.6% |
| Cost Reimbursement | $1.8M | 1.5% |
| ZEVTERA | $351K | 0.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $121.4M (+24%)
License And Other grew +1162% year on yearRoyalty -12% year on year
Segment Latestquarter on quarteryear on year
- Royalty$56.3M$56.3MQoQ +2.1%year on year -12%+2.1%-12%
- Xacduro$22.4M$22.4MQoQ +24%year on year +109%+24%+109%
- Giapreza$22.3M$22.3MQoQ +10%year on year +29%+10%+29%
- License And Other$11.5M$11.5MQoQ +689%year on year +1162%+689%+1162%
- Xerava$6.7M$6.7MQoQ +156%year on year -5.0%+156%-5.0%
- Cost Reimbursement$1.8M$1.8MQoQ -year on year +125%-+125%
- ZEVTERA$351.0K$351.0KQoQ -20%year on year +3.5%-20%+3.5%
Biotechnology
Ranks #54 of 143 by Smart Score